Viewing Study NCT00237159


Ignite Creation Date: 2025-12-24 @ 3:02 PM
Ignite Modification Date: 2026-02-13 @ 9:20 AM
Study NCT ID: NCT00237159
Status: COMPLETED
Last Update Posted: 2011-03-23
First Post: 2005-10-09
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Sponsor: Novartis Pharmaceuticals
Organization:

Study Overview

Official Title: Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis
Status: COMPLETED
Status Verified Date: 2011-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: